IRIS
STELLA, STEFANIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.596
EU - Europa 2.347
AS - Asia 1.978
SA - Sud America 390
AF - Africa 336
OC - Oceania 4
Totale 8.651
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.488
SG - Singapore 976
RU - Federazione Russa 871
IT - Italia 694
CN - Cina 436
BR - Brasile 342
IE - Irlanda 222
VN - Vietnam 186
CI - Costa d'Avorio 185
IN - India 126
FR - Francia 87
UA - Ucraina 86
DE - Germania 85
CA - Canada 73
GB - Regno Unito 61
SN - Senegal 60
KR - Corea 59
FI - Finlandia 44
NG - Nigeria 39
SE - Svezia 33
IQ - Iraq 29
PL - Polonia 28
MX - Messico 25
BE - Belgio 24
ES - Italia 24
AR - Argentina 22
TR - Turchia 22
JP - Giappone 21
NL - Olanda 21
BD - Bangladesh 20
ZA - Sudafrica 19
CZ - Repubblica Ceca 16
HK - Hong Kong 16
UZ - Uzbekistan 14
ID - Indonesia 12
MA - Marocco 10
CH - Svizzera 9
AT - Austria 8
IL - Israele 8
SA - Arabia Saudita 8
AE - Emirati Arabi Uniti 6
GR - Grecia 6
IR - Iran 6
KE - Kenya 6
PK - Pakistan 6
PY - Paraguay 6
EC - Ecuador 5
EG - Egitto 5
HU - Ungheria 5
KZ - Kazakistan 5
TN - Tunisia 5
AU - Australia 4
CO - Colombia 4
LT - Lituania 4
NO - Norvegia 4
PE - Perù 4
RO - Romania 4
BJ - Benin 3
DO - Repubblica Dominicana 3
PS - Palestinian Territory 3
RS - Serbia 3
TT - Trinidad e Tobago 3
VE - Venezuela 3
AZ - Azerbaigian 2
BG - Bulgaria 2
CY - Cipro 2
KG - Kirghizistan 2
LB - Libano 2
LV - Lettonia 2
MY - Malesia 2
NP - Nepal 2
OM - Oman 2
UY - Uruguay 2
AM - Armenia 1
BO - Bolivia 1
CG - Congo 1
CL - Cile 1
DZ - Algeria 1
ET - Etiopia 1
GD - Grenada 1
GL - Groenlandia 1
HN - Honduras 1
HR - Croazia 1
IS - Islanda 1
JM - Giamaica 1
JO - Giordania 1
MN - Mongolia 1
NA - Namibia 1
PH - Filippine 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
Totale 8.651
Salva come PNG Salva come JPEG
Città #
Singapore 648
Santa Clara 524
Dallas 481
Moscow 430
Chandler 326
Chicago 231
Ashburn 227
San Jose 225
Dublin 221
Catania 189
Abidjan 185
Los Angeles 98
Jacksonville 96
Beijing 94
Boardman 85
Hefei 85
Kochi 79
Lauterbourg 65
Cambridge 60
Dakar 59
Lawrence 59
Seoul 58
Council Bluffs 56
Andover 55
New York 55
Civitanova Marche 54
Ho Chi Minh City 48
Palermo 43
Hanoi 42
Grafing 35
Nanjing 34
São Paulo 32
Milan 31
Buffalo 30
Des Moines 30
Wilmington 29
Toronto 28
The Dalles 27
Dong Ket 26
Columbus 25
Brussels 24
Montreal 24
Orem 23
Turku 22
Warsaw 22
Rome 21
Tokyo 21
Abuja 19
Munich 19
Bari 18
Chennai 18
Johannesburg 17
Lagos 16
Lappeenranta 15
London 14
Brno 13
Hong Kong 13
Messina 13
San Mateo 13
Seattle 13
Stockholm 13
Ottawa 12
Rio de Janeiro 12
Santa Venerina 12
Belo Horizonte 11
Brooklyn 11
Haiphong 11
Jiaxing 11
Manchester 11
Nanchang 11
Amsterdam 10
Baghdad 10
Boston 10
Falls Church 10
Tashkent 10
Aci Catena 9
Bremen 9
Da Nang 9
Phoenix 9
Saint Petersburg 9
Atlanta 8
Curitiba 8
Houston 8
Brasília 7
Casablanca 7
Denver 7
Frankfurt am Main 7
Hanover 7
Hebei 7
Helsinki 7
Jakarta 7
Poplar 7
Pune 7
Querétaro 7
Redmond 7
San Francisco 7
Elk Grove Village 6
Florence 6
Miami 6
Mumbai 6
Totale 5.912
Salva come PNG Salva come JPEG
Nome #
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 225
Activation of the IGF axis in thyroid cancer: Implications for tumorigenesis and treatment 183
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 179
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 168
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 167
AKT Inhibitors: New Weapons in the Fight Against Breast Cancer? 167
An Optimized NGS Workflow Defines Genetically Based Prognostic Categories for Patients with Uveal Melanoma 165
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 164
Mutational Analysis of BRCA1 and BRCA2 Genes in Breast Cancer Patients from Eastern Sicily 161
Biomarkers and prognostic factors for malignant pleural mesothelioma 160
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives 160
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report 159
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 158
Associations of classic Kaposi sarcoma with common variants in genes that modulate host immunity 156
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts 155
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 154
A case of high-risk AML in a patient with advanced systemic mastocytosis 152
B-ALL relapses after autologous stem cell transplantation associated with a shift from e1a2 to e14a2 BCR-ABL transcripts: A case report 151
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice 151
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. 146
Effect of combined epigenetic treatments and ectopic NIS expression on undifferentiated thyroid cancer cells 145
Efficacy of Nilotinib in a CML Patient Expressing the Three-way Complex Variant Translocation t(2;9;22) 144
The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the BCR-ABL1 Rearrangement in Philadelphia-Positive Leukemias 142
New insights in thyroid cancer and p53 family proteins 137
Rufloxacin induced photosensitization in bio-models of increasing complexity 134
Mechanistic Translation of Melanoma Genetic Landscape in Enriched Pathways and Oncogenic Protein-Protein Interactions 132
Next generation sequencing in a cohort of patients with rare sarcoma histotypes: A single institution experience 130
Double-face activity of resveratrol in voluntary runners: assessment of DNA damage by comet assay. 129
Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer 127
Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report 127
Opportunities and challenges of liquid biopsy in thyroid cancer 126
Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias 125
Combined inhibition of bcl2 and bcr-abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells 125
Detection and clinical implications of a novel BCR-ABL1 E12A2 insertion/deletion in a CML patient expressing the E13A2 isoform 122
The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study 120
High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability 117
Successful management of a pregnant patient with chronic myeloid leukemia receiving standard dose imatinib 117
Glucose-dependent effect of insulin receptor isoforms on tamoxifen antitumor activity in estrogen receptor-positive breast cancer cells 117
Correlates of Human Herpesvirus-8 DNA detection among adults in Italy without Kaposi sarcoma 116
A Multiplex Assay for Fast PIK3CA Hotspot Mutation Characterization in a Single Specimen by 3-Color Digital PCR Analysis 115
Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far 115
In Silico Prediction of BRCA1 and BRCA2 Variants with Conflicting Clinical Interpretation in a Cohort of Breast Cancer Patients 114
Rapid decline of philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 BCR-ABL1 fusion transcript: A case report 113
Second-line dasatinib therapy improved compliance and deep molecular responses in imatinib-intolerant chronic myeloid leukemia patients 111
Uncommon long-term survival in a patient with chronic myeloid leukemia 110
Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma 110
Approcci Terapeutici Innovativi per il Trattamento di Cellule di Leucemia Mieloide Cronica Resistenti ad Imatinib Mesilato 109
Molecular pathogenesis and treatment perspectives for hypereosinophilia and hypereosinophilic syndromes 109
Suppression of survivin induced by BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs 108
Targeting BCL-2 as a therapeutic strategy for primary p210BCR-ABL1-positive B-ALL cells 107
Effective targeting of breast cancer stem cells by combined inhibition of Sam68 and Rad51 105
No Benefit from Hydroxyurea Pre-Treatment in Frontline Chronic Myeloid Leukemia Therapy and Evidence of Quantitative Changes in the BCR::ABL1 Transcript Level 102
Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study 94
Single-Cell Analysis in the Omics Era: Technologies and Applications in Cancer 93
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation. 93
Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors 92
Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase 92
THE ROLE OF SPARC IN CHRONIC MYELOID LEUKEMIA 91
The Role of New Technologies in Myeloproliferative Neoplasms 90
Diagnosis of Chronic Myeloid Leukemia Early in Pregnancy 88
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia 86
REThinking the role of the RET oncogene in breast cancer 84
High BCR-ABL/GUS(IS) Levels at Diagnosis Are Associated with Unfavorable Responses to Standard Dose Imatinib 83
Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia 82
The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy 82
PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance 80
Personalized strategies for CML patients considering discontinuation of tyrosine kinase inhibitors treatment 71
Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis 70
Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia 69
The other side of the coin: dissecting molecular mechanisms behind hereditary breast cancer in search of therapeutic opportunities 69
Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain 65
Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes 63
Bridging the Gap: the role of MDM2 inhibition in overcoming treatment resistance in breast cancer 53
Totale 8.831
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.454
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.454
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202171 0 0 0 0 0 0 0 0 0 3 33 35
2021/2022435 20 67 11 7 78 8 64 15 25 11 30 99
2022/20231.036 68 82 56 119 58 148 13 201 209 14 46 22
2023/2024553 44 83 26 24 19 132 8 33 7 23 112 42
2024/20252.107 30 330 79 152 412 291 166 64 75 143 255 110
2025/20264.062 253 240 584 288 657 1.041 442 89 227 241 0 0
Totale 8.831